Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables (2021 - 2025)

Historic Receivables for BridgeBio Pharma (BBIO) over the last 4 years, with Q3 2025 value amounting to $116.5 million.

  • BridgeBio Pharma's Receivables changed N/A to $116.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.5 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2024, which is 10085.07% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Receivables stood at $116.5 million.
  • BridgeBio Pharma's Receivables' 5-year high stood at $116.5 million during Q3 2025, with a 5-year trough of $2.4 million in Q4 2023.
  • For the 4-year period, BridgeBio Pharma's Receivables averaged around $54.3 million, with its median value being $43.5 million (2021).
  • Over the last 5 years, BridgeBio Pharma's Receivables had its largest YoY gain of 10085.07% in 2024, and its largest YoY loss of 10085.07% in 2024.
  • Over the past 4 years, BridgeBio Pharma's Receivables (Quarter) stood at $10.2 million in 2021, then tumbled by 76.89% to $2.4 million in 2023, then soared by 100.85% to $4.7 million in 2024, then soared by 2367.56% to $116.5 million in 2025.
  • Its last three reported values are $116.5 million in Q3 2025, $76.9 million for Q2 2025, and $115.3 million during Q1 2025.